公开(公告)号：EP2531498A1

公开(公告)日：2012-12-12

申请号：EP11703560.0

申请日：2011-02-04

申请人： IRM LLC ,  Novartis AG

发明人： TELLEW, John E. ,  PAN, Shifeng ,  WAN, Yongqin ,  XIE, Yongping ,  WANG, Xing ,  WANG, Xia ,  HUANG, Shenlin ,  LIU, Zuosheng ,  ZHANG, Qiong

IPC分类号： C07D401/14 ,  C07D471/04 ,  A61K31/4353 ,  A61P35/00

CPC分类号： C07D471/04 ,  A61K31/444 ,  A61K31/506 ,  A61K31/519 ,  A61K45/06 ,  C07D401/14

摘要： The invention provides a novel class of compounds of Formula (I) (wherein A, Y, R
2 , R
3 , R
4 and R
5 are defined in the summary of the invention), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

公开(公告)号：EP2057146A1

公开(公告)日：2009-05-13

申请号：EP07814982.0

申请日：2007-09-24

申请人： IRM LLC ,  NOVARTIS AG

发明人： ALBAUGH, Pamela ,  CHOPIUK, Gregory S. ,  DING, Qiang ,  HUANG, Shenlin ,  LIU, Zuosheng ,  PAN, Shifeng ,  REN, Pingda ,  WANG, Xia ,  WANG, Xing ,  XIE, Yongping ,  ZHANG, Chengzhi ,  ZHANG, Qiong ,  ZHANG, Guobao ,  POON, Daniel ,  RENHOWE, Paul ,  SENDZIK, Martin

IPC分类号： C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D417/14 ,  A61K31/506 ,  A61P35/00

CPC分类号： C07D403/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D417/14

摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn, KDR, c-Kit, LCK, PDGF-R, b-Raf, c-Raf, SAPK2, Src, Tie2 and TrkB kinases.

摘要翻译： 本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症的方法，特别是涉及Abl，ARG，BCR异常活化的疾病或病症 -Abl，BRK，EphB，Fms，Fyn，KDR，c-Kit，LCK，PDGF-R，b-Raf，c-Raf，SAPK2，Src，Tie2和TrkB激酶。

公开(公告)号：EP2167498B1

公开(公告)日：2010-09-15

申请号：EP08770796.4

申请日：2008-06-12

申请人： IRM LLC

发明人： BURSULAYA, Badry ,  CHENG, Dai ,  JIANG, Jiqing ,  KARANEWSKY, Donald, S. ,  LIU, Yi ,  PAN, Shifeng ,  WAN, Yongqin ,  WANG, Xia ,  XIE, Yun, Feng ,  YANG, Yang

IPC分类号： C07D413/14 ,  C07D413/02 ,  A61K31/536 ,  A61P37/02

CPC分类号： C07D413/14 ,  C07D413/02

公开(公告)号：EP1758892A1

公开(公告)日：2007-03-07

申请号：EP05759571.2

申请日：2005-06-09

申请人： IRM LLC

发明人： REN, Pingda ,  WANG, Xia ,  ZHANG, Guobao ,  DING, Qiang ,  YOU, Shuli ,  ZHANG, Qiong ,  CHOPIUK, Greg ,  ALBAUGH, Pamela A. ,  SIM, Taebo ,  GRAY, Nathanael Schiander

IPC分类号： C07D403/04 ,  A61K31/4178

CPC分类号： C07D403/04 ,  C07D401/14 ,  C07D403/14 ,  C07D405/14 ,  C07D417/14

摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, PDGF-R, trkB, c-SRC, BMX, FGFR3, b-RAF, SGK, Tie2, Lck, JNK2 2, MKK4, c-RAF, MKK6, SAPK2 and SAPK2 kinases.

公开(公告)号：EP1899329B1

公开(公告)日：2011-10-05

申请号：EP06774386.4

申请日：2006-06-30

申请人： IRM LLC

发明人： ZHANG, Guobao ,  REN, Pingda ,  WANG, Xia ,  GRAY, Nathanael S. ,  SIM, Taebo

IPC分类号： C07D403/14 ,  C07D403/04 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14 ,  A61K31/495 ,  A61P35/00

CPC分类号： C07D413/14 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D409/14

摘要： The invention provides, compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Alk, Abl, BRK, Blk, BMX, CSK, c-Src, c-Raf, EGFR, Fes, FGFR3, Fms, Fyn, IGF-IR, IR, IKKα, IKKβ, JAK2, JAK3, KDR, Lck, Met, p70S6k, Ros, Rskl, SAPK2α, SAPK2β, SAPK3, SIK, Tie2, TrkB and/or WNK3 kinases.

公开(公告)号：EP2044036B1

公开(公告)日：2011-05-04

申请号：EP07812739.6

申请日：2007-07-10

申请人： IRM LLC

发明人： ALBAUGH, Pamela A. ,  HE, Yun ,  JIANG, Songchun ,  REN, Pingda ,  WANG, Xia ,  WANG, Xing ,  XIE, Yongping

IPC分类号： C07D239/42 ,  C07D401/12 ,  C07D401/14 ,  A61K31/506 ,  A61P35/00

CPC分类号： C07D401/14 ,  C07D239/42 ,  C07D401/12

摘要： The invention provides a novel class of compounds of the Formula (I): in which the symbols have the meanings given in the description and claims, to pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of FGFR3 kinase.

公开(公告)号：EP2027123B1

公开(公告)日：2011-02-23

申请号：EP07797441.8

申请日：2007-05-11

申请人： IRM LLC

发明人： REN, Pingda ,  WU, Baogen ,  ZHANG, Guobao ,  XIE, Yongping ,  OKRAM, Barun ,  NIKULIN, Victor ,  WANG, Xia ,  CHOI, Ha-soon

IPC分类号： C07D471/14 ,  A61K31/4375

CPC分类号： C07D471/14

摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the AbI, Bcr-Abl, Bcr-Abl(T315I), ALK5BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-IR, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFRα, Ros, SAPK2α, SGK, SIK, Syk, Tie2 and TrkB kinases.

摘要翻译： 本发明提供了一类新化合物，包含此类化合物的药物组合物以及使用此类化合物治疗或预防与异常或失调的激酶活性相关的疾病或病症，特别是涉及AbI，Bcr-Abl异常活化的疾病或病症的方法 ，Bcr-Abl（T315I），ALK5BLK，BMX，BRK，C-kit，c-RAF，CSK，c-SRC，EGFR，Fes，FGFR3，Flt3，Fms，Fyn，IGF-IR，IR， ，JAK（3），KDR，Lck，NLK，p70S6K，PDGFRα，Ros，SAPK2α，SGK，SIK，Syk，Tie2和TrkB激酶。

公开(公告)号：EP1899329A1

公开(公告)日：2008-03-19

申请号：EP06774386.4

申请日：2006-06-30

申请人： IRM LLC A Delware Limited Liability Company

发明人： ZHANG, Guobao ,  REN, Pingda ,  WANG, Xia ,  GRAY, Nathanael S. ,  SIM, Taebo

IPC分类号： C07D403/14 ,  C07D403/04 ,  C07D401/14 ,  C07D409/14 ,  C07D413/14 ,  A61K31/495 ,  A61P35/00

CPC分类号： C07D413/14 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D409/14

摘要： The invention provides, compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Alk, Abl, BRK, Blk, BMX, CSK, c-Src, c-Raf, EGFR, Fes, FGFR3, Fms, Fyn, IGF-IR, IR, IKKα, IKKβ, JAK2, JAK3, KDR, Lck, Met, p70S6k, Ros, Rskl, SAPK2α, SAPK2β, SAPK3, SIK, Tie2, TrkB and/or WNK3 kinases.

公开(公告)号：EP2274302A2

公开(公告)日：2011-01-19

申请号：EP09727043.3

申请日：2009-03-30

申请人： IRM LLC

发明人： WAN, Yongqin ,  PAN, Shifeng ,  ZHANG, Guobao ,  WANG, Xia ,  XIE, Yun Feng ,  JIANG, Jiqing ,  PHILLIPS, Dean ,  YANG, Yang

IPC分类号： C07D401/14 ,  C07D407/14 ,  C07D409/14 ,  C07D471/04 ,  A61K31/496 ,  A61P17/00 ,  A61P19/00

CPC分类号： C07D401/14 ,  C07D407/14 ,  C07D409/14 ,  C07D471/04

摘要： The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1,4,5-trisphosphate 3-kinase B (ITPKb).

公开(公告)号：EP2167498A1

公开(公告)日：2010-03-31

申请号：EP08770796.4

申请日：2008-06-12

申请人： IRM LLC

发明人： BURSULAYA, Badry ,  CHENG, Dai ,  JIANG, Jiqing ,  KARANEWSKY, Donald, S. ,  LIU, Yi ,  PAN, Shifeng ,  WAN, Yongqin ,  WANG, Xia ,  XIE, Yun, Feng ,  YANG, Yang

IPC分类号： C07D413/14 ,  C07D413/02 ,  A61K31/536 ,  A61P37/02

CPC分类号： C07D413/14 ,  C07D413/02

摘要： The invention provides a novel class of compounds of formula (I), pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or dysregulated B cell activities, particularly diseases or disorders that involve aberrant activation of inositol 1, 4, 5- trisphosphate 3 -kinase B (ITPKb).

摘要翻译： 本发明提供了一类新的式（I）化合物，包含这些化合物的药物组合物以及使用这些化合物治疗或预防与B细胞活性异常或失调相关的疾病或病症，特别是涉及异常活化 肌醇1,4,5-三磷酸3-激酶B（ITPKb）。